Table 2.
Sample characteristics, by type of tapering.
| Variable | Percentage or mean | SD | n | |
|---|---|---|---|---|
| Daily tiny-step tapering | Starting dose a | 0.73 | 0.49 | 554 |
| Total dose reduction (as % of starting dose) | 82.2 | 23.2 | 554 | |
| Per-day dose reduction (as % of previous dose) | 4.5 | 8.7 | 554 | |
| Used venlafaxine | 40.0 | 554 | ||
| Used paroxetine | 24.1 | 554 | ||
| Age | 53.9 | 13.8 | 554 | |
| Percentage women | 81.3 | 554 | ||
| Risk factors | ||||
| Fear withdrawal | 38.4 | 554 | ||
| Previous unsuccessful attempt | 55.0 | 554 | ||
| Possible relapse | 7.4 | 554 | ||
| Slow metaboliser | 1.8 | 554 | ||
| High dose | 3.7 | 554 | ||
| Problems when starting | 3.2 | 554 | ||
| Problems when missing dose | 6.9 | 554 | ||
| Antidepressant use > 2 years | 82.1 | 554 | ||
| No risk factors | 6.3 | 554 | ||
| Number of risk factors | 2.0 | 1.0 | 554 | |
| Length tapering trajectory in days | 70.1 | 35.1 | 554 | |
| Used stabilisation strip | 6.2 | 554 | ||
| Weekly large-step tapering | Starting dose a | 0.45 | 0.44 | 52 |
| Total dose reduction (as % of starting dose) | 85.8 | 16.3 | 50 | |
| Per-week dose reduction (as % of previous dose) | 33.4 | 17.3 | 50 | |
| Used venlafaxine | 51.8 | 52 | ||
| Used paroxetine | 23.2 | 52 | ||
| Age | 55.1 | 13.1 | 52 | |
| Percentage women | 84.8 | 52 | ||
| Risk factors | ||||
| Fear withdrawal | 43.8 | 52 | ||
| Previous unsuccessful attempt | 45.5 | 52 | ||
| Possible relapse | 0.0 | 52 | ||
| Slow metaboliser | 3.6 | 52 | ||
| High dose | 0.0 | 52 | ||
| Problems when starting | 12.5 | 52 | ||
| Problems when missing dose | 7.1 | 52 | ||
| Antidepressant use > 2 years | 68.8 | 52 | ||
| No risk factors | 9.8 | 52 | ||
| Number of risk factors | 1.8 | 1.0 | 52 | |
| Length tapering trajectory in days | 76.5 | 32.6 | 52 | |
| Used stabilisation strip | 18.8 | 52 |
a
Expressed in units of daily defined dose.